Raab & Moskowitz Asset Management LLC Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Raab & Moskowitz Asset Management LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 1.4% in the fourth quarter, Holdings Channel reports. The firm owned 133,747 shares of the biopharmaceutical company’s stock after purchasing an additional 1,884 shares during the period. Pfizer comprises approximately 1.2% of Raab & Moskowitz Asset Management LLC’s holdings, making the stock its 23rd biggest position. Raab & Moskowitz Asset Management LLC’s holdings in Pfizer were worth $3,851,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Spinnaker Trust grew its position in shares of Pfizer by 78.3% during the 4th quarter. Spinnaker Trust now owns 86,160 shares of the biopharmaceutical company’s stock valued at $2,481,000 after purchasing an additional 37,829 shares in the last quarter. K.J. Harrison & Partners Inc grew its position in shares of Pfizer by 13.4% during the 4th quarter. K.J. Harrison & Partners Inc now owns 41,801 shares of the biopharmaceutical company’s stock valued at $1,203,000 after purchasing an additional 4,952 shares in the last quarter. Callan Capital LLC grew its position in shares of Pfizer by 8.8% during the 4th quarter. Callan Capital LLC now owns 11,576 shares of the biopharmaceutical company’s stock valued at $333,000 after purchasing an additional 932 shares in the last quarter. Herold Advisors Inc. lifted its holdings in shares of Pfizer by 1.6% during the 4th quarter. Herold Advisors Inc. now owns 63,762 shares of the biopharmaceutical company’s stock worth $1,836,000 after acquiring an additional 1,026 shares during the last quarter. Finally, Stanley Laman Group Ltd. lifted its holdings in shares of Pfizer by 411.2% during the 4th quarter. Stanley Laman Group Ltd. now owns 55,599 shares of the biopharmaceutical company’s stock worth $1,601,000 after acquiring an additional 44,722 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PFE. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Stock Performance

Pfizer stock opened at $25.40 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $143.83 billion, a PE ratio of 70.56, a P/E/G ratio of 1.14 and a beta of 0.61. The firm has a fifty day simple moving average of $26.96 and a two-hundred day simple moving average of $28.39. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the company earned $1.14 earnings per share. The company’s revenue for the quarter was down 41.3% compared to the same quarter last year. Research analysts expect that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.61%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.